Q-omics provides the consensus-scored ASAH2B profile across patient tissues and cancer cell-line models. ASAH2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ASAH2B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ASAH2B RNA expression shows 19,926 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where ASAH2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASAH2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASAH2B survival associations across molecular data types. ASAH2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASAH2B RNA expression–survival associations across cancer types. High ASAH2B expression shows unfavorable associations in HNSC, ACC, CESC and LUAD, but favorable associations in SCLC and KIRC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ASAH2B RNA expression.
This table summarizes ASAH2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ASAH2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASAH2B shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, BRCA, COAD and LIHC. The HNSC box plot shows higher ASAH2B RNA expression in tumor versus normal tissue (log2 FC = +0.387, t-test p < 0.001).
This table shows molecular features associated with ASAH2B in patient tissues and cancer cell lines. In patient samples, ASAH2B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ASAH2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
